COVID-19 vaccine development timeline

- Design & exploratory preclinical studies
- Process development, preclinical & toxicology studies
- Clinical trial authorisation
- Rolling regulatory review

Clinical trials:
- Phase 1: Safety
- Phase 2: Immune response
- Phase 3: Efficacy Confirmation

Large scale production (at risk)

Phases overlap to progress development in the shortest time possible

Safety assessment ongoing throughout
COVID-19 vaccine workstreams over time

- Expert Working Group
- NIBSC independent batch testing preparation
- Pre-clinical analysis
- Interim analysis
- Quality analysis
- NIBSC independent batch testing begins
- Final analysis

Timeline:
- June
- July
- Aug
- Sep
- Oct
- Nov
- 30 Nov
- Dec
Process: appraisal of evidence

Vaccine safety & efficacy
- UK Epidemiology
- Health inequalities
- Primary care
- Secondary care
- Mathematical modelling
- Deployment expertise

Joint Committee on Vaccination and Immunisation (JCVI)

Advice for Phase 1
Next phase: to be determined
The first phase of the programme:
prevention of mortality and maintenance of health and social care systems

| Offer vaccination according to the estimated risk of dying from COVID-19 | Predominantly age-based programme | Implement vaccination with due attention locally to mitigating health inequalities |
The **first phase** of the programme

**Offer vaccination**

<table>
<thead>
<tr>
<th></th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Residents in a care home for older adults and their carers</td>
</tr>
<tr>
<td>2</td>
<td>All those 80 years of age and over. Frontline health and social care workers</td>
</tr>
<tr>
<td>3</td>
<td>All those 75 years of age and over</td>
</tr>
<tr>
<td>4</td>
<td>All those 70 years of age and over. Clinically extremely vulnerable individuals</td>
</tr>
<tr>
<td>5</td>
<td>All those 65 years of age and over</td>
</tr>
<tr>
<td>6</td>
<td>All individuals aged 16 years to 64 years with underlying health conditions which put them at higher risk of serious disease and mortality</td>
</tr>
<tr>
<td>7</td>
<td>All those 60 years of age and over</td>
</tr>
<tr>
<td>8</td>
<td>All those 55 years of age and over</td>
</tr>
<tr>
<td>9</td>
<td>All those 50 years of age and over</td>
</tr>
</tbody>
</table>
The **first phase** of the programme

Implement vaccination

<table>
<thead>
<tr>
<th>Local NHS</th>
<th>Local public health teams</th>
<th>Local leaders &amp; communities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitigate health inequalities, as might occur in relation to</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• access to healthcare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• deprivation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• ethnicity</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Promote good vaccine uptake